The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28686445 |
39 |
Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. |
Sun Yat-Sen University |
| 27301679 |
21 |
Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket. |
Takeda Pharmaceutical |
| 24758746 |
36 |
Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia. |
Janssen Pharmaceutica |
| 15887951 |
29 |
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. |
Monash University (Parkville Campus) |
| 19631533 |
126 |
Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one. |
Pfizer |
| 16913726 |
33 |
Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction. |
Università |
| 15006407 |
15 |
Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 12668004 |
76 |
Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors. |
Pfizer |
Search and Browse
